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ABSTRACT
Background: The presence of dual HlV-l/HIV-2 infection in Ghana and the different 
drug requirements for the treatment of HlV-1 and HIV-2 presents difficulties for the 
treatment of dual infections with both viruses. 
Objectives: To determine the prevalence of the dual sero-positive profile in treatment 
naive patients at a principal ART Clinic in Accra, Ghana and to investigate if rapid 
screening assays could be useful for diagnosis. 
Design: A cross-sectional study.
Setting: A principal antiretroviral treatment centre in Accra, Ghana. 
Subjects: Three hundred and twenty eight antiretroviral treatment naive patients.
Results: A total of 12 (3.7%) of patients seen were dual seropositive. There was a 
slight tendency of dual seropositive females being older than their HIV-l counterparts 
(p=0.088, CI=-l 0.833 to 0.753). Eight of the 12 of the dual seropositives were reactive 
for Genie II and were considered as possibly infected with both HIV-I and HIV-2. 
Seven (87.5%) of Genie II dual seropositives had strong intensities (> 1+) on both 
HIV-2 specific bands (sgp105 and gp36) on Innolia. CD4 counts were not significantly 
different in dual seropositives as compared to HIV-1 infected patients. 
Conclusions: Dual HIV-l/HIV-2 seropositives (and possibly infections) may be common 
especially in older women. The Genie II will be useful as a supplemental rapid test 
for rapid and accurate differentiation of HIV-l and HIV-2 antibodies at treatment 
centres. 
INTRODUCTION
Due to the presence of individuals with both HlV-2 
and dual HIV-l/HIV-2 seropositive (and infection) 
profiles in West Africa, there are challenges in the 
antiretroviral treatment programmes in this setting. 
Highly active antiretroviral regimens (HAART) which 
efficiently suppress HIV-l may not be useful for HIV-
2 (1), and this may adversely affect the treatment of 
dual infected patients (2). 
 Although the highest absolute and relative 
proportion of dual seropositivity has been seen in 
female commercial sex workers (CSW) elsewhere 
(3), significant proportions have been seen in other 
populations in Ghana (4, 5). In these studies, HIV-l was 
shown to be predominant, with dual seropositivity 
being more common than HlV-2 alone. 
 HIV-l but not HIV-2 DNA is mostly detected in 
peripheral blood lymphocytes of dual seropositive 
individuals (4,6-8), the converse is also possible 
(9). The diagnostic problem has therefore been 
the accurate detection of HIV-2 antibodies. With 
appropriate screening algorithms, a strong correlation 
between dual seropositivity and infections is possible 
(10). Very few rapid tests have been evaluated for 
their differential ability to distinguish between HIV-l 
and HIV-2 infections. However, one of the previously 
cited studies has shown that patients with dual 
seropositive profiles on Genie II HIV-l/HIV-2 (BioRad 
Laboratories, France) are more likely to be infected 
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with HlV-2 (9). Although rapid tests are likely to give 
some unclear results for differentiating between HIV-l 
and HIV-2 infections, a stringent screening algorithm 
that includes Genie II HIV-I /HIV-2 may be useful in 
predicting dual infections. 
 With the scale-up of antiretroviral therapy in 
Ghana, there is the need to understand the dynamics 
of patients with the dual seropositive profile in order 
to establish optimal sero-screening procedures for 
the effective treatment of all HIV infected patients. 
This study therefore determined the prevalence 
of the dual seropositive profile in treatment naive 
patients at a principal ART Clinic in Accra, Ghana, 
and investigated if the Genie II HIV-l HIV-2, BioRad, 
Marnes La Coquette, France (Genie II), could be used 
as a second screening test to correctly diagnose dual 
seropositivity. 
MATERIALS AND METHODS 
HIV/AIDS patients: A randomly selected set of 328 
HIV/AIDS treatment naive individuals attending 
the Fevers Unit (a principal ART treatment centre in 
Ghana), Korle-Bu Teaching Hospital, being a large 
subset of patients used in a previous study (11), 
were included in this study. These patients were 
obtained by convenient sampling between August 
2003 and September 2004. Ethical approval was 
granted by the University of Ghana Medical School 
Ethics Committee (MS-Et/M.04-P02/2003-04) and 
written consent was obtained from all patients before 
enrolment. Demographic data and CD4 counts were 
also obtained from patient files. 
Diagnosis of HIV-I and HIV-2 infections: Serological 
differentiation for HIV-l and HIV-2 antibodies using 
plasma obtained from EDTA tubes was done with the 
Rapitest (Morwell Diagnostics GmbH, Gewerbestr, 
Switzerland), and all dual HIV -l/ HIV-2 seropositivity 
confirmed with a line-immunoassay, lnnolia N.V 
lnnoGenietics, Antwerp, Belgium, according to 
manufacturer’s instructions using the l6 hour 
incubation as previously described (12). Bands on 
test strips were rated as indeterminate (±) or reactive 
(1 +, > 1+ or 3+) in relation to the intensity of the 
internal control bands on strips. If both HIV-l specific 
bands (sgpl20 and gp4l) were present (>1+) and the 
maximum banding intensity for one HIV-2 specific 
band (sgpl05 or gp36) was 1+, the patient had HIV-1 
antibodies. However, if only one HIV-1 specific band 
was present (>1 +), the maximum rating of ± was 
allowed on one HIV-2 specific band. A similar but 
converse interpretation was used for the diagnosis 
of HlV-2 seropositivity. Plasma sample that exceeded 
these maximum ratings had both HIV-1 and HIV-2 
antibodies (dual seropositive). 
 HIV-2 infection in dual seropositivity has 
been shown to be high with Genie II (9). All dual 
seropositives on Innolia with strong intensities (>1+) 
on all envelope bands for HIV-l and HIV-2 (sgp120, 
gp4l, sgp105 and gp36) and dual seropositive on 
Genie II, were considered as likely HIV-l and HIV-2 
infections. A cross-section of 13 HIV-1 seropositives by 
lnnolia were also screened with Genie II as controls, 
but plasma was not available for lnnolia and Genie 
II testing for the only HIV-2 patient identified during 
the study. This patient was subsequently excluded 
from all analyses. All 13 HIV -1 seropositives screened 
were concordant with lnnolia results, and had strong 
intensities (>1 +) for all HIV -1 envelope specific bands 
(sgp120 and gp41). 
Statistical analysis: The Independent T-test was used 
to compare the age differences, gender proportions 
and CD4+ counts of dual and HIV-1 seropositives and 
chi-squared test used in comparing the proportion of 
women who were dual and HIV-l infected. The SPSS 
v14.0 for Windows (SPSS Inc., Chicago, USA), was 
used for all statistical analysis. 
RESULTS
A total of 114 males and 214 females participated in 
the study. The ages of the male ranged from 18 to 68 
years (n=110), while that of the female was from 21 to 
64 years (n=211). Twelve (3.7%) of the patients were 
dual seropositive. In the absence of DNA for HIV-1 and 
HIV-2 PCR, the stringent criterion described earlier 
(see methods) was used in classifying dual infections. 
Only eight (2.7%) of the 12 dual seropositives were 
therefore considered as infected with both HIV-1 
and HIV-2 (Table 1), with six (75%) being women. 
Genierally, Genie II dual seropositives mostly had 
strong intensities (> 1+) on both HIV -2 specific bands 
(sgp105 and gp36) of Innolia. The only exception 
was CAL 187 which had a background reactivity for 
sgp105 (Table 1). 
 There was a slight difference, though not 
statistically significant, between the ages of HIV-1 
and dual seropositive patients (P=0.130, CI=-9.364 
to 1.203). Although there was a tendency of dual 
seropositive females being older than their HIV-l 
counterparts (p=0.088, CI=-10.833 to 0.753), this 
reduced when only dual infected females were 
considered (p=0.233, CI=-10.249 to 2.506). There was 
no difference in the proportion of females who were 
HlV-1 infected as compared to those who were dual 
seropositive (p=0.228, OR=2.756, CI=0.594 to 12.881), 
and those who were dual infected (p >0.717, OR=1.655, 
CI=0.329 to 8.337). 
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Table 1
Comparative reactivity of dual HIV-1 /HIV-2 seropositive plasma using Innolia and Genie II
   Innolia results 
Sample  Serologic   *Innolia band reactivities  Genie II 
ID  profile  sgpl20  gp41  sgpl05  gp36  results 
CALl0  Dual HIV 1/2  3+  3+  neg  > 1+  HIV-1 
CAL33  Dual HIV 1/2  3+  3+  3+  3+  Dual 
CAL88  Dual HIV 1/2  3+  3+  neg  3+  HIV-1 
CAL90  Dual HIV 1/2  3+  3+   3+  3+  Dual 
CAL105  Dual HIV 1/2  3+  3+  3+  3+  Dual 
CALl56  Dual HIV 1/2  3+  3+  3+  3+  Dual 
CALl79  Dual HIV 1/2  3+  3+  3+  3+  Dual 
CALl87  Dual HIV 1/2  3+  3+  >± (<1+)  3+  Dual 
CAL244  Dual HIV 1/2  3+  3+  neg  3+  HIV-1 
CAL246  Dual HIV 1/2  3+  3+  neg  3+  HIV-1 
CAL298  Dual HIV 1/2  3+  3+  3+  3+  Dual 
CAL364  Dual HIV 1/2  3+  3+  >1+  3+  Dual 
All plasma samples were screened Rapitest, Morwell Diagnostics GmbH, Gewerbestr, Switzerland, and 
dual seropositives confirmed. *The line immunoassay, Innolia, Innogentics, Antwerp, Belgium, was used 
for confirmatory testing and interpretation done according to manufacturers’ instruction. sgpl20/gp4l and 
sgpl05/gp36 are HIV-l and HIV-2 specific bands on Innolia respectively. Genie II HIV-1/HIV-2 (BioRad, 
Marnes La Coquette, France) results have been shown for all Innolia dual seropositives. 
 Mean (range) CD4 counts were 245 (5 to 593) 
and 291 (1 to 1299) for dual (n=6) and HIV-l (n=110) 
seropositives respectively. There was no significant 
difference between CD4 counts for dual seropositives 
as compared to those with HIV-l infection (p=0.699, 
CI=-0.188.362 to 280.369). CD4 counts were Genierally 
unavailable at the time of the study because 
antiretroviral therapy had just begun. 
DISCUSSION
Although the proportion of dual seropositives seen 
was small (Table 1), their occurrence suggests that 
effective screening for HIV-l and HIV-2 antibodies for 
patients about to begin ART using appropriate tests is 
essential. This will enable appropriate regimens to be 
given to those infected with HIV-2 either as dual or in 
single infections. Previous studies have reported dual 
infections in dual seropositives in Ghana (4, 8), and 
the results of this study indicate that dual infections 
are definitely present, albeit with a low prevalence. 
Also, baseline information for understanding the 
trends of dual seropositivity in treatment naive 
patients is now available. 
 This study did not consider whether or not any 
of the participants were commercial sex workers. 
Therefore, our observation that women were not likely 
to have a higher proportion of dual seropositive or 
infection as described in the high prevalence seen in a 
previous study, (3), may be due to the small numbers 
of dual seropositives and infection seen. However, 
the data provides valuable information for future 
comparison with prevalence rates that may be seen 
later. Almost 29 (40%) of the CSW in Senegal in a 
particular study on dual infections were Ghanaians 
(13). This suggests that international migration may 
contribute to the current prevalence of dual infections 
attending treatment centres in Ghana. The need to 
understand the dynamics becomes increasingly 
important since international migration may affect 
prevalence rates and therefore policy. However, 
continuous screening with a confirmatory assay may 
overburden the already taxed health care budget for 
ART. Just as two different screening tests can be used 
to diagnose HIV infection (14), the possibility of using 
rapid screening assays to discriminate HIV-1 and 
HIV-2 antibodies is emphasised. This is especially 
so since prevalence rates are relatively low. 
 HIV-2 infections are common in Genie II dual 
seropositives (9), and the main problem of dual 
infections is related to the correct diagnosis of HIV-
2 (4,6-8). Although Genie II does not have sgp105 
peptides or recombinant proteins, the majority of 
Genie II dual seropositives had strong sgpl05 HIV-2 
specific bands on the lnnolia (Table 1). Therefore, 
screening with Rapitest and confirming with the 
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Genie II provides a clear distinction between dual 
seropositives with two HIV-2 specific bands, and 
those with only gp36 bands on lnnolia. The reactivity 
on the Genie 11 HlV-2 spot may reflect high antibody 
titers that may reflect an ongoing or just subdued 
HIV-2 infection (15). This is confirmed by the fact that 
all monotypic HIV-2 infections on lnnolia we have 
seen in our routine screening turned out to be HIV-2 
on Genie II and had both sgpl05 and gp36 bands on 
lnnolia (data not shown). 
 A  possible explanation for the Genie II reactivity 
for CAL 187 could be an early infection with HIV-2. 
Super infection with either HIV-l or HIV-2 is also 
possible (13), so this patient may therefore have an 
active HIV-2 infection which is being established. 
Alternatively, HIV-1 may have outgrown HIV-2 in vivo 
resulting in a reduction in HIV-2 specific antibodies 
overtime. This suggestion is supported by the report 
that patients with advanced decline in CD4 counts 
may not have or may loose HlV-2 when co-infected 
with HIV-1 (15). CAL l87 had a very low CD4 count 
(85 cells/ml) (data not shown) and therefore reflects 
this picture. The possibility of the presence of a 
Genietically aberrant HIV-2 strain can also not be 
ruled out. Though very little work has been done 
on HIV-2 subtypes (16), there is a possibility that 
like HIV-1 subtype 0 (17), different assays may have 
different abilities for detecting HIV-2. 
 Our results confirm those of others (3), and 
show that dual seropositives may have similar 
immunological characteristics as compared to HIV 
-1 infected individuals. There is a need for this 
proposed algorithm of using a first rapid assay that 
can discriminate between HlV-l/HIV-2 antibodies and 
Genie II to be compared with PCR results to enable 
a decision to be made on its usefulness for routine 
screening of patients beginning HAART in Ghana. 
Just as two rapid assays can be used in diagnosing 
HIV infections (14), this study shows that it will be 
possible to use a similar approach in diagnosing dual 
seropositivity and possibly dual infections. 
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